Ketan Desai Blog | Talkmarkets | Page 1
CEO of International Medical Consultants, IMC Radiology, and CMO of Levolta Pharma

Ketan Desai, MD, PhD, is the Founder and Chief Executive Officer of IMC Radiology, the founder and Chief Medical Officer of LeVolta Pharma, Founder and CEO of UBDoc (an artificial intelligence based company for health care) and a part-time practicing physician. One of his inventions was acquired ... more


Latest Posts
1 to 11 of 11 Posts
E Pitfalls Of Biotechnology Investing
How capital distorts the availability of biotechnology companies.
E Wither Flexion?
A new study highlights that there are likely fewer candidates for Flexion's star osteoarthritis treatment and this could affect the stock price of Flexion considerably.
Is India's Economic Potential Over-Hyped?
An examination of the culture and demographics of India in relation to its economic potential.
E Ford Model T And Personalized Medicine
While technology marches on, the economics of personalized medicines just don’t add up. Will they be like costly trinkets being displayed in a museum that we can watch at a distance but not own?
E Only Trump Can Go To Russia
Investment implications of Trump's Russia and China policies.
E Two Lessons From My Biogen Trade
One can be wrong and make money and be right and lose money. Here is how I made money on Biogen Inc.
E Betting Against Buffett - VRSN
Using TA to bet against Verisign.
E 15 Bear Market Charts
These charts demonstrate that the bear market is here.
E Nothing Intuitive About Intuitive Surgical
After ISRG announced it had a new surgical machine that had been approved by the FDA, its stock shot up into the 500s. So is ISRG a buy? Not according to Ketan Desai who explains in this brief article the simple reasons why he bought ISRG puts.
E Results Of My Sarepta Trade
Anticipating the FDA rejection of Sarepta Therapeutics's drug application for eteplirsen, Ketan Desai explains how he made money with an options strategy.
The Case For Shorting Myriad Genetics
Many articles have been written about Myriad Genetics (MYGN) – some bullish, some bearish. This is a bearish article, looking at the company from a different angle.
1 to 11 of 11 Posts